#biopharmaceuticals #DecipheraPharmaceuticals #Romvimza #tenosynovialgiantcelltumours #TGCT #vimseltinib #FDAapprovel #Deciphera #raretumourtype #symptomatictenosynovialgiantcelltumours #tyrosinekinaseinhibitor #CSF1R #CSF1Rinhibitor #MOTIONclinicaltrial
pharmatimes.com/news/fda-app...
pharmatimes.com/news/fda-app...
FDA approves Deciphera’s Romvimza for rare tumour type - PharmaTimes
Tenosynovial giant cell tumours can cause pain, stiffness, swelling and movement limitations
pharmatimes.com
February 27, 2025 at 10:02 AM
💊FDA Approval Update | #Hyrnuo (#sevabertinib)
🔸For #HER2-mutant non-small cell lung cancer #NSCLC
⚙️Reversible tyrosine kinase inhibitor targets #EGFR and #HER2 protein
🌟MedChemExpress provides #Sevabertinib for research use.
#NSCLC #TyrosineKinaseInhibitor #TKI #FDA #FDAApproval
🔸For #HER2-mutant non-small cell lung cancer #NSCLC
⚙️Reversible tyrosine kinase inhibitor targets #EGFR and #HER2 protein
🌟MedChemExpress provides #Sevabertinib for research use.
#NSCLC #TyrosineKinaseInhibitor #TKI #FDA #FDAApproval
November 24, 2025 at 9:01 PM
💊FDA Approval Update | #Hyrnuo (#sevabertinib)
🔸For #HER2-mutant non-small cell lung cancer #NSCLC
⚙️Reversible tyrosine kinase inhibitor targets #EGFR and #HER2 protein
🌟MedChemExpress provides #Sevabertinib for research use.
#NSCLC #TyrosineKinaseInhibitor #TKI #FDA #FDAApproval
🔸For #HER2-mutant non-small cell lung cancer #NSCLC
⚙️Reversible tyrosine kinase inhibitor targets #EGFR and #HER2 protein
🌟MedChemExpress provides #Sevabertinib for research use.
#NSCLC #TyrosineKinaseInhibitor #TKI #FDA #FDAApproval